NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight.
about
The mechanisms of cachexia underlying muscle dysfunction in COPDReference values for vastus lateralis fiber size and type in healthy subjects over 40 years old: a systematic review and metaanalysisCelastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stressHypoxaemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease.Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuliExercise training modulates the nitric oxide synthase profile in skeletal muscle from old rats.2D-DIGE proteomic analysis of vastus lateralis from COPD patients with low and normal fat free mass index and healthy controlsReduced HDAC2 in skeletal muscle of COPD patients.An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patientsImpact of supplementation with amino acids or their metabolites on muscle wasting in patients with critical illness or other muscle wasting illness: a systematic review.Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary diseaseNuclear factor-kappa B signaling in skeletal muscle atrophy.Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease.Hypoxemia in patients with COPD: cause, effects, and disease progressionGenome-wide mRNA expression profiling in vastus lateralis of COPD patients with low and normal fat free mass index and healthy controls.Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients.Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia.Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary diseaseMolecular and cellular mechanisms of skeletal muscle atrophy: an update.Obesity, insulin resistance, and skeletal muscle nitric oxide synthaseChronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Phenotypes of chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease.Clinical management of chronic obstructive pulmonary disease and asthma in an obese patient.Diaphragm adaptations in patients with COPD.Recombinant rat CC16 protein inhibits LPS-induced MMP-9 expression via NF-κB pathway in rat tracheal epithelial cells.Epigenetic drugs in the treatment of skeletal muscle atrophy.Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease.COPD as a systemic disease.Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivityImpact of nutritional status on body functioning in chronic obstructive pulmonary disease and how to intervene.MuRF-1 and atrogin-1 protein expression and quadriceps fiber size and muscle mass in stable patients with COPD.Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease.Pathophysiology of muscle dysfunction in COPD.Redox control of skeletal muscle atrophy.Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.Molecular mechanism of sarcopenia and cachexia: recent research advances.Immunobiology of Nitric Oxide and Regulation of Inducible Nitric Oxide Synthase.Endothelial glutathione-S-transferase A4-4 protects against oxidative stress and modulates iNOS expression through NF-kappaB translocation.
P2860
Q26828616-4522A1FF-9424-4A86-9523-74807FAB0AA3Q27027496-78A78ABF-CE51-4ADE-A689-9CBE421BF44DQ28533974-8D7D77E2-B058-499B-B765-8BA031757219Q30478614-62B36E74-79F5-480E-8411-E73A3EA918F5Q33332170-6F6FCBF2-1F9D-4A1D-85AE-127C16AC09B9Q33567653-EF4D1BB3-FC91-414C-98BF-B74253B7466EQ33634631-48AC7ED1-F4C2-4A55-ACA3-F832AF006879Q33708989-9D585ABB-D7AD-47ED-BA85-459435FA5658Q33901722-735CD643-9871-46BF-B179-F4161951983AQ34061404-DF2A2297-5FB7-4954-9B67-3B898501C6B0Q34419261-4AD5B877-8797-42C9-88D2-562F3C6E6AA9Q34442689-63E420E7-8A96-478D-B127-7198BF320032Q34593476-3ABCC390-DD55-4742-8A7D-91D110CB39F2Q34625439-4A92814F-0BCE-4D1D-82F3-114DB5C61ADFQ35023212-E1B0EDFF-164D-445A-A16B-7CFD840B65A8Q35097330-672D8B4B-C9FD-496F-9425-B7D2C6F861FAQ35111740-3D521CE7-41E7-4F9F-A969-041F3E7090DDQ35254722-625AED6B-E674-4666-929D-6C71F4B1D6B2Q35564212-1AA4F174-5DC0-4E44-B30E-721197340A4DQ36179105-631ACC00-1346-4764-9D14-A932236C1AC2Q36320847-5C6EC558-B364-4B3C-9A42-95A330BF4634Q36443665-D12C79DF-DA8A-4931-BA66-59A7C35F3724Q37008634-156219AC-EF74-4DFD-A0C7-05F682D1FC91Q37016623-2C45A588-5038-4CDE-8638-DCA2D1B2932CQ37030847-35389C61-078B-4865-A777-9B9B0D3FAA25Q37064535-AAB2117E-C457-4CD0-85D6-E09627125F7EQ37071107-18988E4F-4701-46B7-947D-39DD672F3F97Q37088443-10015425-8A04-42C5-818D-512332EDC0F8Q37115925-4E03F8F2-0D77-4CFA-94CB-D7D863435082Q37139528-42C05E0B-0A85-4CB1-B6AE-C1D075D11E17Q37162234-22995E86-8C8E-4D8F-8E36-745EFC093F17Q37187270-652CE66F-1C1D-4BF0-9814-B520329A3F9CQ37728557-3515E8DE-57D8-45B4-A6EE-D2154AE6F646Q38023517-B7B47498-9888-4D88-ADA4-9E9A92D3B255Q38091961-45CB6420-02B6-4D9D-A900-21FD2F6DB540Q38748962-56F61E48-BD29-4382-8368-15049E0D7478Q39016673-C1C7D271-21D8-43E9-AC06-3D9F3530CF84Q39094397-FCC467BF-1AA2-4D8B-9CC5-D813485BD5E4Q39271619-32A115BD-3E80-4B4E-BF81-DAC4E39F3A72Q39981459-04800567-6B4A-470F-947F-C0A5FB1E76FF
P2860
NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
NF-kappaB activation and iNOS ...... with COPD and low body weight.
@en
NF-kappaB activation and iNOS ...... with COPD and low body weight.
@nl
type
label
NF-kappaB activation and iNOS ...... with COPD and low body weight.
@en
NF-kappaB activation and iNOS ...... with COPD and low body weight.
@nl
prefLabel
NF-kappaB activation and iNOS ...... with COPD and low body weight.
@en
NF-kappaB activation and iNOS ...... with COPD and low body weight.
@nl
P2093
P2860
P356
P1433
P1476
NF-kappaB activation and iNOS ...... with COPD and low body weight.
@en
P2093
P2860
P304
P356
10.1136/THX.2003.017640
P407
P577
2004-06-01T00:00:00Z